Abstract
Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Current Drug Targets
Title:Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Volume: 14 Issue: 11
Author(s): Barbara Di Benedetto, Rainer Rupprecht and Boldizsár Czéh
Affiliation:
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Abstract: Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Export Options
About this article
Cite this article as:
Benedetto Di Barbara, Rupprecht Rainer and Czéh Boldizsár, Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/1389450111314110011
DOI https://dx.doi.org/10.2174/1389450111314110011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Pharmacotherapy in Pedatric PTSD: A Developmentally-Focused Review of the Evidence
Current Psychopharmacology Thalamocortical Oscillations: Local Control of EEG Slow Waves
Current Topics in Medicinal Chemistry Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery Lamotrigine Induced Whole Body Tics: A Case Report and Literature Review
Current Drug Safety Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/ Β-Catenin Pathway
CNS & Neurological Disorders - Drug Targets Substituted Aminobenzothiazole Derivatives of Tacrine: Synthesis and Study on Learning and Memory Impairment in Scopolamine-Induced Model of Amnesia in Rat
Mini-Reviews in Medicinal Chemistry Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets How to Find Candidate Drug-targets for Antiepileptogenic Therapy?
Current Neuropharmacology Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Comparative Studies on Phospholipase A2 as a Marker for Gut Microbiota- liver-brain Axis in a rodent Model of Autism
Current Proteomics Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery